BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21356164)

  • 1. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
    Yarom N; Jonker DJ
    Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer in review: the role of the EGFR pathway.
    Saif MW
    Expert Opin Investig Drugs; 2010 Mar; 19(3):357-69. PubMed ID: 20095919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
    Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive molecular classifiers in colorectal cancer.
    Bohanes P; LaBonte MJ; Winder T; Lenz HJ
    Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where now for anti-EGF receptor therapies in colorectal cancer?
    Shaw PH; Adams RA
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted treatments in colorectal cancer: state of the art and future perspectives.
    Arnold D; Seufferlein T
    Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor as a therapeutic target in veterinary oncology.
    Bergkvist GT; Yool DA
    Vet Comp Oncol; 2011 Jun; 9(2):81-94. PubMed ID: 21569194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
    Spano JP; Milano G; Vignot S; Khayat D
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
    Bianchini D; Jayanth A; Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends.
    Katsios C; Ziogas DE; Roukos DH; Baltogiannis G
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):5-8. PubMed ID: 23265143
    [No Abstract]   [Full Text] [Related]  

  • 19. [EGF receptors in colorectal cancers].
    Spano JP; Vignot S
    Bull Cancer; 2007; 94(7 Suppl):F171-6. PubMed ID: 17964993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?
    Tejpar S; Piessevaux H
    Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():2-10. PubMed ID: 24512508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.